Picture of Scilex Holding Co logo

SCLX Scilex Holding Co Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m+46.69%
3m+16.05%
6m+9.22%
1yr-79.43%
Volume Change (%)
10d/3m+104.05%
Price vs... (%)
52w High-73.8%
50d MA+57.36%
200d MA+17.21%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin-211.36%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Scilex Holding Co EPS forecast chart

Profile Summary

Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    March 31st, 2024
    Incorporated
    November 9th, 2022
    Public Since
    January 11th, 2021
    No. of Shareholders
    315
    No. of Employees
    106
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Capital Market
    Shares in Issue
    181,189,935

    SCLX Share Price Performance

    Upcoming Events for SCLX

    Similar to SCLX

    Picture of 60 Degrees Pharmaceuticals logo

    60 Degrees Pharmaceuticals

    us flag iconNASDAQ Capital Market

    Picture of Aadi Bioscience logo

    Aadi Bioscience

    us flag iconNASDAQ Capital Market

    Picture of Acasti Pharma logo

    Acasti Pharma

    us flag iconNASDAQ Capital Market

    Picture of Agriforce Growing Systems logo

    Agriforce Growing Systems

    us flag iconNASDAQ Capital Market

    Picture of Aptorum logo

    Aptorum

    us flag iconNASDAQ Capital Market

    FAQ